stockrow
Monday 9 November 2026
Export PRQR’s income statement to Excel — free account
ProQR Therapeutics N.V.
PRQRProQR Therapeutics N.V.’s revenue for fiscal 2025 (year ended December 2025) was $18.0 million, down 12.0% from fiscal 2024.
- Revenue
- +135.0%
- EPS
- +28.6%
- Free cash flow
- −1.06%
- Total debt
- +8.71%
Quarter to June 2026, against a year earlier
1.35
0.02
+1.50%
Follow PRQR
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 2 | 4 | 7 | 20 | 18 | 21 | +83.1% | 20 | 18 | 28 | +15.5% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | +100.0 pt | ||||||
| EBT | (43) | (49) | (44) | (63) | (53) | (73) | (68) | (30) | (30) | (48) | (49) | +1.1% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (4,546.80) | (1,605.02) | (426.97) | (147.90) | (265.09) | (228.57) | (265.1) pt | ||||||
| Net income | (43) | (49) | (44) | (64) | (53) | (73) | (68) | (30) | (30) | (48) | (48) | +1.1% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.06 | 0.09 | 0.24 | 0.17 | 0.20 | n/m | |||||
| Earnings | (1.85) | (1.94) | (1.29) | (1.55) | (1.06) | (1.14) | (0.96) | (0.38) | (0.35) | (0.45) | (0.46) | (14.5%) | ||||||
| Cash flow | (1.62) | (1.56) | (0.99) | (1.20) | (1.07) | (0.48) | (1.01) | 0.29 | (0.46) | (0.57) | (0.51) | (11.0%) | ||||||
| Capex | (0.12) | (0.01) | (0.01) | (0.02) | (0.02) | (0.01) | (0.01) | 0.09 | (0.02) | (0.01) | (0.01) | (23.3%) | ||||||
| Free cash flow | (1.74) | (1.56) | (1.00) | (1.22) | (1.09) | (0.49) | (1.02) | 0.38 | (0.48) | (0.58) | (0.52) | (11.5%) | ||||||
| Book value | 2.52 | 1.75 | 3.21 | 2.56 | 1.29 | 2.09 | 0.96 | 0.55 | 1.11 | 0.53 | 0.84 | (15.9%) | ||||||
| Shares, m | 23 | 25 | 34 | 41 | 50 | 64 | 72 | 81 | 86 | 105 | 107 | +18.2% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | 0.00 | 57.44 | 23.90 | 11.15 | 11.82 | 6.92 | 20.9 | ||||||
| P/B | — | — | — | — | — | 3.84 | 3.56 | 3.76 | 2.38 | 3.81 | 1.61 | 3.5 | ||||||
| EV/Sales | — | — | — | — | — | 0.00 | 35.64 | 6.66 | 3.72 | 6.58 | 1.06 | 10.5 | ||||||
| EV/FCF | — | — | — | — | — | (11.01) | (2.08) | 2.15 | (1.86) | (1.94) | (0.40) | (2.9) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (38) | (40) | (34) | (49) | (54) | (31) | (72) | 23 | (39) | (60) | (56) | +5.2% | |||||
| Capex | (3) | 0 | 0 | (1) | (1) | (1) | (1) | 7 | (2) | (1) | (1) | (9.4%) | ||||||
| Free cash flow | (41) | (40) | (34) | (50) | (55) | (31) | (73) | 30 | (41) | (61) | (57) | +4.6% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 61 | 48 | 118 | 116 | 80 | 194 | 140 | 94 | 124 | 77 | 101 | +2.5% | |||||
| Net debt | (59) | (46) | (114) | (111) | (67) | (170) | (93) | (124) | (157) | (99) | (130) | +5.9% | ||||||
| Shareholders’ equity | 59 | 44 | 109 | 105 | 65 | 134 | 69 | 45 | 96 | 56 | 92 | (0.6%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (47.11) | (74.42) | (45.82) | (48.55) | (43.52) | (40.42) | (32.02) | (18.46) | (18.15) | (30.86) | (31.53) | +16.3 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | (54.60) | (95.54) | (56.62) | (59.24) | (62.69) | (73.43) | (67.73) | (53.67) | (42.73) | (62.93) | (58.29) | (8.3) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 133 | 130 | 118 | 154 | 150 | 182 | 130 | 156 | 166 | 187 | — | +3.9% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 | 0.05 | 0.12 | 0.10 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026
ProQR Therapeutics N.V. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ELDN Eledon Pharmaceuticals, Inc. | $211.7M | — (loss-making) | — | — | n/m | −28.02% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PYXS Pyxis Oncology, Inc. | $198.6M | — (loss-making) | — (loss-making) | — | n/m | −5.46% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| IFRX InflaRx N.V. | $192.3M | — (loss-making) | — (loss-making) | −128.93% (below 0%: shrinking) | n/m | +59.76% (above 0%: growing) | 14,029.95% | 0.00% | Compare |
| TRDA Entrada Therapeutics, Inc. | $191.5M | — (loss-making) | — (loss-making) | −43.93% (below 0%: shrinking) | n/m | −7.05% (below 0%: shrinking) | 100.00% | (4,606.52%) | Compare |
| PRQR ProQR Therapeutics N.V. | $190.5M | — (loss-making) | — (loss-making) | +135.03% (above 0%: growing) | n/m | −1.06% (below 0%: shrinking) | 100.00% | (100.72%) | |
| RNA Atrium Therapeutics, Inc. | $185.8M | — (loss-making) | — (loss-making) | — | n/m | — | 100.00% | (752.93%) | Compare |
| CGEN Compugen Ltd. | $185.7M | 5.2× | — (loss-making) | +107.00% (above 0%: growing) | n/m | −155.42% (below 0%: shrinking) | (3.54%) | (339.62%) | Compare |
| KROS Keros Therapeutics, Inc. | $183.7M | — (loss-making) | — (loss-making) | +120.22% (above 0%: growing) | n/m | +6.87% (above 0%: growing) | 100.00% | 32.04% | Compare |
| ACOG Alpha Cognition Inc. | $180.5M | — (loss-making) | — (loss-making) | +267.56% (above 0%: growing) | n/m | −109.25% (below 0%: shrinking) | 94.80% | (127.29%) | Compare |
| Median of peers | $188.6M | — | — | +107.00% | — | −7.05% | 100.00% | (63.64%) |